An innovative prognostic model specific to ccRCC and related to ARESs has been constructed, incorporating three key ARGs: TIMP1 (Tissue Inhibitor of Metalloproteinases 1), PECAM1 (Platelet and Endothelial Cell Adhesion Molecule 1), and CDKN1A (Cyclin Dependent Kinase Inhibitor 1A). This evidence concerns the gene CDKN1A and nonpapillary renal cell carcinoma.